Tizanidine HCl

Synopsis, Chemistry

APIs // Active Pharmaceutical Ingredients

30 API Suppliers, 13 USDMF, 2 CEP/COS, 6 JDMF, 8 EU WC, 3 KDMF, 7 NDC API, 14 Listed Suppliers

DEVELOPMENTS

1 Drug(s) in Development

1 Drug(s) in Development

PRICE INFORMATION

API Reference Price, API Exports, API Imports, FDF Exports

DOSSIERs // Finished Dosage Formulations

97 Dossiers, 70 FDA Orange Book, 2 Europe, 2 Canada, 23 Listed Dossiers

DRUG PRODUCT COMPOSITION

TABLET;ORAL - EQ 2MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - EQ 4MG BASE, CAPSULE;ORAL - EQ 2MG BASE, CAPSULE;ORAL - EQ 4MG BASE, CAPSULE;ORAL - EQ 6MG BASE

TABLET;ORAL - EQ 2MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - EQ 4MG BASE
CAPSULE;ORAL - EQ 2MG BASE
CAPSULE;ORAL - EQ 4MG BASE
CAPSULE;ORAL - EQ 6MG BASE

RELATED EXCIPIENT COMPANIES

Suppliers, 36 Kerry, 18 Roquette, 11 Sigachi Industries, 10 BASF, 10 Corel Pharma Chem, 8 Gangwal Healthcare, 8 Seppic, 8 Microlex e.U, 6 Gangwal Chemicals, 6 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 6 Lonza Capsugel, 6 DFE Pharma, 5 Ideal Cures Pvt Ltd, 4 SPI Pharma, 4 ACG Worldwide, 4 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 3 Doshion Polyscience, 3 Ingredion Pharma Solutions, 3 Kima Chemical, 2 Prachin Chemical, 2 Nanjing Well Pharmaceutical, 2 Vasa Pharmachem, 2 The Dow Chemical Company, 2 Qualicaps, 2 DKSH, 1 Jai Radhe Sales, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Actylis, 1 Pharmatrans-Sanaq, 1 Finar, 1 Pfanstiehl, 1 Aeon Procare

EXCIPIENTS BY APPLICATIONS

54 Fillers, Diluents & Binders, 48 Coating Systems & Additives, 28 Direct Compression, 22 Controlled & Modified Release, 20 Disintegrants & Superdisintegrants, 19 Granulation, 15 Thickeners and Stabilizers, 14 Taste Masking, 12 Co-Processed Excipients, 11 Film Formers & Plasticizers, 9 Lubricants & Glidants, 9 Empty Capsules, 6 Chewable & Orodispersible Aids, 4 Vegetarian Capsules, 4 API Stability Enhancers, 4 Topical, 3 Rheology Modifiers, 2 Parenteral, 2 Coloring Agents, 2 Solubilizers, 2 Emulsifying Agents

GLOBAL SALES INFORMATION

16 US Medicaid Prescriptions, 8 Finished Drug Prices

MARKET PLACE

8 APIs, 2 DOSSIERS // FDF

ANALYTICAL SOLUTION(s)

3 USP Standards, 5 Other Ref. Standards

DIGITAL CONTENT

1 Data Compilations & Company Tracker #PharmaFlow, 24 News

Full Screen View

Delpor

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Delpor Advances Pipeline to Include Spasticity Maintenance Therapy with $2.5 Million NIH Grant for Tizanidine Implant

Details:

Proceeds from the financing will be used for the advancement of the company’s tizanidine implant product (DLP-208) for moderate-severe spasticity. DLP-208 can provide sustained therapy for several months, while only requiring a 10-minute procedure in an outpatient setting.

Lead Product(s): Tizanidine HCl

Therapeutic Area: Musculoskeletal Product Name: DLP-208

Highest Development Status: UndisclosedProduct Type: Small molecule

Partner/Sponsor/Collaborator: National Institutes of Health

Deal Size: $2.5 million Upfront Cash: Undisclosed

Deal Type: Funding November 16, 2021

ASK
US

Upload
your Marketing & Sales content

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Find Drugs in Development News & Deals for Tizanidine HCl

Tizanidine HCl

Tizanidine HCl

Synopsis

Chemistry

APIs // Active Pharmaceutical Ingredients

30 API Suppliers

13 USDMF

2 CEP/COS

6 JDMF

8 EU WC

3 KDMF

7 NDC API

14 Listed Suppliers

DEVELOPMENTS

1 Drug(s) in Development

PRICE INFORMATION

API Reference Price

API Exports

API Imports

FDF Exports

DOSSIERs // Finished Dosage Formulations

97 Dossiers

70 FDA Orange Book

2 Europe

2 Canada

23 Listed Dossiers

DRUG PRODUCT COMPOSITION

TABLET;ORAL - EQ 2MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - EQ 4MG BASE

CAPSULE;ORAL - EQ 2MG BASE

CAPSULE;ORAL - EQ 4MG BASE

CAPSULE;ORAL - EQ 6MG BASE

RELATED EXCIPIENT COMPANIES

Suppliers

36 Kerry

18 Roquette

11 Sigachi Industries

10 BASF

10 Corel Pharma Chem

8 Gangwal Healthcare

8 Seppic

8 Microlex e.U

6 Gangwal Chemicals

6 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

6 Lonza Capsugel

6 DFE Pharma

5 Ideal Cures Pvt Ltd

4 SPI Pharma

4 ACG Worldwide

4 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

3 Doshion Polyscience

3 Ingredion Pharma Solutions

3 Kima Chemical

2 Prachin Chemical

2 Nanjing Well Pharmaceutical

2 Vasa Pharmachem

2 The Dow Chemical Company

2 Qualicaps

2 DKSH

1 Jai Radhe Sales

1 Qianhao Chemical (Hebei) Co., Ltd

1 Actylis

1 Pharmatrans-Sanaq

1 Finar

1 Pfanstiehl

1 Aeon Procare

EXCIPIENTS BY APPLICATIONS

54 Fillers, Diluents & Binders

48 Coating Systems & Additives

28 Direct Compression

22 Controlled & Modified Release

20 Disintegrants & Superdisintegrants

19 Granulation

15 Thickeners and Stabilizers

14 Taste Masking

12 Co-Processed Excipients

11 Film Formers & Plasticizers

9 Lubricants & Glidants

9 Empty Capsules

TABLET;ORAL - EQ 2MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons